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PKC-θ is selectively enriched in T cells and speciﬁcally translocates to immunological
synapse where it mediates critical T cell receptor signals required for T cell activation,
differentiation, and survival. T cells deﬁcient in PKC-θ are defective in their ability to differ-
entiate into inﬂammatory effector cells that mediate actual immune responses whereas,
their differentiation into regulatory T cells (Treg) that inhibits the inﬂammatory T cells is
enhanced.Therefore, the manipulation of PKC-θ activity can shift the ratio between inﬂam-
matory effector T cells and inhibitory Tregs, to control T cell-mediated immune responses
that are responsible for autoimmunity and allograft rejection. Indeed, PKC-θ-deﬁcient mice
are resistant to the development of severalTh2 andTh17-dependent autoimmune diseases
and are defective in mounting alloimmune responses required for rejection of transplanted
allografts and graft-versus-host disease. Selective inhibition of PKC-θ is therefore con-
sidered as a potential treatment for prevention of autoimmune diseases and allograft
rejection.
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INTRODUCTION
T cells that are newly migrated out of thymus are naïve T cells
incapable of mediating immune responses. Engagement of anti-
gens with their T cell receptors (TCR) initiates the activation and
differentiation programs that transform naïve T cells into inﬂam-
matory Th1, Th2, and Th17 effector cells or regulatory T cells
(Treg), both of which participate in actual immune responses. The
interference with molecules involved in T cell activation and dif-
ferentiation is therefore considered an effective strategy to control
the overwhelming immune responses that mediate autoimmu-
nity and allograft rejection. However, most molecules involved
in the processes of T cell activation and differentiation are not
likely to be good targets for interference or inhibition because they
also play essential roles in other cell types and signaling path-
ways. The ideal targets should meet at least the following criteria:
(1) they selectively regulate T cell function; (2) small molecule
inhibitors of them are easy to isolate or develop; (3) rather than
inhibit, they actually promote Treg function. Ideally, inhibition
of the target molecule should inhibit inﬂammatory T cells, and
at the same time, enhance the suppressive function of Tregs. In
this review, we summarize the evidence that supports PKC-θ
as an excellent target for development of immunosuppressive
agents.
PKC-θ IS SELECTIVELY ENRICHED IN T CELLS
PKC-θ belongs to a family of serine/threonine kinases that consists
of 12 different isoforms, each with distinct roles in the regulation
of cellular functions (Newton, 1997). Members of this family can
be divided into three subfamilies (Newton, 1997): conventional
PKCs, including PKC-α, β, and γ, which are activated by Ca2+
and diacylglycerol (DAG); novel PKCs, including PKC-δ, θ, η,
and ε, whose activation is dependent on DAG but is independent
of Ca2+; and the atypical PKCs, PKC-ζ and λ, whose activa-
tion occurs independently of both Ca2+ and DAG. PKC-θ was
ﬁrst cloned as a novel PKC predominantly expressed in skeleton
muscle (Osada et al., 1992; Chang et al., 1993) and found to be sig-
niﬁcantly enriched in hematopoietic compartments and skeleton
muscle (Baier et al., 1994; Altman et al., 2000; Bauer et al., 2000).
In hematopoietic compartments, PKC-θ is primarily expressed
in T cells, but not B cells, and this has also been conﬁrmed by
in situ hybridization to mouse whole body sections (Bauer et al.,
2000). The selective expression pattern of PKC-θ strongly suggests
it plays a unique function in T cell compartments, and therefore
may be a good immunosuppressive target for controlling T cell-
mediated immunity. However, it is important to point out that T
cells also express other isoforms of PKC (Bauer et al., 2000). Fur-
thermore, although most studies have so far focused on PKC-θ
function in T cells, there is evidence supporting that PKC-θ is also
expressed and play a role in other tissues including muscle (Kim
et al., 2004; Benoit et al., 2009; Paoletti et al., 2010), platelets (Nagy
et al., 2009; Harper and Poole, 2010; Cohen et al., 2011), natural
killer (NK) cells (Aguilo et al., 2009), and likely mast cells (Kem-
puraj et al., 2005). Therefore, inhibition or targeting of PKC-θ for
immunotherapeutic treatments may also affect other tissues in
addition to T cells.
PKC-θ SELECTIVELY TRANSLOCATES TO
IMMUNOLOGICAL SYNAPSE
PKC-θ attracted signiﬁcant attention when it was shown among
all the isoforms of PKC expressed in T cells, PKC-θ selectively
translocates to the immunological synapse (IS), the stable cell–
cell junction formed between T cells and antigen-presenting cells
(Monks et al., 1997, 1998). The IS is a cluster of specialized mem-
brane microdomains where TCR signaling molecules, including
the TCR itself, are assembled (Grakoui et al., 1999). Formation
of the IS is an active process that requires Lck-mediated signals
to initiate re-organization of cytoskeleton (Morgan et al., 2001).
Although there is still some controversy (Lee et al., 2002), it is
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generally believed that the IS serves as the platform that deliv-
ers integrated signals essential for T cell activation (Moran and
Miceli, 1998). The IS consists of three major compartments: the
central supramolecular activation cluster (cSMAC), the peripheral
SMAC (pSMAC), and the distal SMAC (dSMAC; Barouch-Bentov
et al., 2005; Dustin, 2009). The cSMAC was initially referred to
as a signaling structure (Monks et al., 1998; Freiberg et al., 2002)
and is located at the center of the IS. Around this center is the
pSMAC, a ring of LFA-1/ICAM-1 co-localized with the cytoskele-
tal integrin linker talin (Monks et al., 1998). The outermost ring
is the dSMAC, a zone enriched in the CD45 tyrosine phosphatase
(Freiberg et al., 2002). Recently, it was demonstrated that the TCRs
initially microcluster in the dSMAC, and then move through the
pSMAC into the cSMAC, and is believed to be critical for the
generation of continuous TCR signals that are required for T cell
activation (Varma et al., 2006). PKC-θ is recruited to the junc-
tion between the cSMAC and pSMAC and co-localizes with TCRs
in a CD28 co-stimulatory-dependent manner (Monks et al., 1997,
1998; Somersalo et al., 2004). Microscopic studies of IS have shown
that T cells expressing PKC-θ periodically break open the pSMAC
to create an asymmetric focal zone accumulation pattern that relo-
cates to nearby areas where the pSMAC reformed (Sims et al.,
2007). This periodic breaking of the symmetric pSMAC to form a
polarized focal zone allows short bursts of migration, facilitating
T cell interaction with multiple antigen presenting cells (Lindquist
et al., 2004). This observation is also consistent with the asymmet-
ric cell division theory that suggests that the IS leads to asymmetric
cell division, a feature that is important for memory/effector dif-
ferentiationof lymphocytes (Chang et al., 2007). A recent studyhas
identiﬁed a unique region of PKC-θ, called the V3 domain, that is
responsible for the selective translocation of PKC-θ to the IS (Kong
et al., 2011). V3 was found to interact with the SH3 domain of Lck
which is in turn, tethered to the phosphorylated tail of CD28 via
its SH2 domain. The PKC-θ–Lck–CD28 interaction explains why
PKC-θ recruitment to the IS depends on CD28 co-stimulation.
However, in a different study the active kinase domain of
PKC-θ was reported to be essential for PKC-θ translocation into
the IS (Cartwright et al., 2011) and is not clear why there is a dis-
crepancy. One possibility is that the two studies used different
sources of T cells: primary T cells transduced with retrovirus and
a D10 cell line. In contrast to conventional T cells, PKC-θ does
not translocate to IS of Tregs. In fact it is actually sequestered
away from the IS (Zanin-Zhorov et al., 2010), suggesting that
the function of PKC-θ in Tregs is likely to be different from its
functions in conventional T cells. Altogether, the fact that selec-
tive translocation of PKC-θ (but not other isoforms of PKC)
to the IS is critical for T cell activation, strongly suggests it
has unique functions in mediating TCR signals, and that selec-
tive inhibition of PKC-θ could speciﬁcally interfere with T cell
function.
PKC-θ MEDIATES TCR SIGNALS ESSENTIAL
FOR T CELL ACTIVATION
TCR signals are initiated by activation of the Src family protein
tyrosine kinase (PTK) Lck (Weiss and Littman, 1994), which leads
ﬁrst to recruitment of ZAP 70 and then the subsequent recruit-
ment of the adaptor proteins LAT, SLP76, and VAV. LAT then
recruits PLCγ1 (Clements, 2003; Berg et al., 2005) which catalyzes
phosphatidylinositol 4,5-biphosphate into inositol triphosphate
(IP3), a Ca2+ mobilizer and DAG, the PKC-θ activator (Weiss and
Littman, 1994). In addition to DAG, PKC-θ activation seems to
also require phosphorylation of threonine 538 (T538) in its acti-
vation loop (Liu et al., 2002; Lee et al., 2005). Previously, PDK1
was believed to phosphorylate T538 (Liu et al., 2002). However,
a recent study indicates GLK is the upstream kinase responsible
for T538 phosphorylation (Chuang et al., 2011). Upon activa-
tion, PKC-θ mediates the activation of NF-κB, AP-1, and nuclear
factor of activated T cells (NFAT), critical transcription factors
that are required for activation of the IL-2 gene (Sun et al.,
2000; Pfeifhofer et al., 2003). Several adaptor proteins play a
critical role inmediating PKC-θ-inducedNF-κB activation includ-
ing membrane-associated guanylate kinase (MAGUK), CARMA1,
B-cell lymphoma 10 (Bcl 10), and mucosa-associated lymphoid
tissue 1 (MALT1). Together with PKC-θ, these adaptors facilitate
the activation of IKK, leading to the phosphorylation, ubiquitina-
tion, and degradation of IκB. Degradation of IκB releases NF-κB
to the nucleus, where it participates in the activation of target
genes essential for T cell activation (Weil et al., 2003; Lin and
Wang, 2004; Weil and Israel, 2004). Studies using PKC-θ-deﬁcient
T cells or cells overexpressing the constitutively active PKC-θ or
the catalytically inactive form of PKC-θ have demonstrated that
PKC-θ also selectively activates the AP-1 signaling pathway in
T cells (Sun et al., 2000). AP-1 is composed of c-Jun and c-Fos,
which regulate many cellular events (Baier-Bitterlich et al., 1996).
Although the exact mechanism responsible for PKC-θ-mediated
activation of AP-1 is still unclear, several studies have provided
some insight into this process. Ras and MAP kinases: JNK, ERK,
and P38 are all involved in PKC-θ-mediated AP-1 activation
(Baier-Bitterlich et al., 1996; Shaulian and Karin, 2002). Li et al.
(2004) isolated a PKC-θ-interacting upstream MAP kinase, orig-
inally termed Ste20/SPS1-related proline and alanine-rich kinase
(SPAK or PASK), and demonstrated that SPAK selectively inter-
acts with PKC-θ and participates in PKC-θ-mediated activation of
AP-1, but not NF-κB. Activation of T cells through the TCR also
leads to IP3-mediated elevation of cytosolic [Ca2+]i by inducing
Ca2+ inﬂux. Elevated intracellular Ca2+ ultimately leads to acti-
vation of the calcineurin phosphatase, which dephosphorylates
NFAT, resulting in its translocation to the nucleus. Translocated
NFAT cooperates with AP-1 to activate IL-2 expression and it has
been shown that, in the absence of AP-1, NFAT activation can
lead to T cell anergy (Macian et al., 2002). Several studies have
shown that PKC-θ enhances the activation of NFAT by stimulat-
ing Ca2+ inﬂux; TCR-induced Ca2+ inﬂux, and NFAT activation
is defective in T cells from PKCθ−/− mice (Pfeifhofer et al., 2003;
Manicassamy et al., 2006a). Although it is clear that PKC-θ regu-
lates Ca2+ signals via stimulation of PLCγ1, it is not known how
PKC-θ stimulates PLCγ1. The Tek kinase family member Itk may
be the missing link. Itk-deﬁcient T cells display defective Ca2+
inﬂux and PLCγ1 activation (Liu et al., 1998), whereas overex-
pression of Itk leads to stimulation of PLCγ1 activity (Tomlinson
et al., 2004). Therefore, it is possible that PKC-θ regulates PLCγ1
activation via Itk. Altogether, PKC-θ-mediated TCR signaling reg-
ulates multiple signaling pathways including NF-κB, AP-1, and
NFAT that are all critical for T cell activation, which were clearly
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summarized in our previously published review articles (Mani-
cassamy et al., 2006b; Kwon et al., 2010). Inhibition of PKC-θ is
therefore expected to prevent T cell activation by blocking these
pathways.
PKC-θ ENHANCES T CELL SURVIVAL
Productive engagement of the TCR leads to T cell activation,
resulting in cell proliferation and production of IL-2. Proliferating
T cells especially during S phase of the cell cycle are susceptible
to apoptosis (Boehme and Lenardo, 1993; Radvanyi et al., 1996).
The TCR delivers signals that are required not only for stimu-
lating proliferation but also for enhancing survival (Weiss and
Littman, 1994; Boise et al., 1995). Such survival signals ensure the
completion of the T cell activation process that is essential for
differentiating naïve T cells into effectors that can mediate actual
immune responses (Radvanyi et al., 1996). During T cell activa-
tion, survival of the T cells is enhanced by IL-2, which acts as an
extrinsic survival factor. In addition, activated T cells substantially
up-regulate Bcl-xL that intrinsically increases resistance to apopto-
sis (Noel et al., 1996; Radvanyi et al., 1996; Van Parijs et al., 1996).
We and others have shown that PKC-θ is required for the survival
of activated T cells (Barouch-Bentov et al., 2005; Manicassamy
et al., 2006a). PKC-θ−/− T cells undergo apoptosis in response
to TCR stimulation, which correlates with the reduced expres-
sion of NF-κB-dependent Bcl-xL. Forced expression of Bcl-xL and
Bcl-2 restores the survival of PKC-θ−/− T cells and exogenous
IL-2 can partially overcome the defective survival and prolifera-
tion of PKC-θ−/− T cells. Similar to primary T cells, PKC-θ is also
required for the survival of T cell lines such as Jurkat. It has been
shown that PKC-θ promotes Jurkat survival by phosphorylating
Bad and thereby inactivating its function (Villalba et al., 2001).
However, primary T cells deﬁcient in PKC-θ showed compara-
ble levels of Bad phosphorylation to that of wild-type (WT) T
cells (Barouch-Bentov et al., 2005), suggesting that the observed
apoptosis of PKC-θ−/− T cells is unlikely to be due to lack of
Bad phosphorylation. Other pathways may also be involved in
the apoptosis of PKC-θ−/− T cells. For example, up-regulation of
pro-apoptotic molecule Bim might be partially responsible for the
observed apoptosis in PKC-θ−/− T cells (Barouch-Bentov et al.,
2005). Wan and DeGregori (2003) reported that inhibition of
NF-κB leads to an increase in the expression of pro-apoptotic
protein p73 . Since PKC-θ−/− T cells are defective in NF-κB acti-
vation, it is possible that down-regulated p73 may contribute to
the apoptosis of PKC-θ−/− T cells. Because T cell survival ensures
T cell-mediated immune responses, one of the mechanisms for
PKC-θ to regulate immune responses is to enhance T cell survival
and this is conﬁrmed by our allograft rejection study discussed
later in the review.
PKC-θ PROMOTES THE DIFFERENTIATION OF NAÏVE T CELLS
TO INFLAMMATORY Th17 CELLS
Differentiation of naïve T cells into speciﬁc T helper lineages is
a critical checkpoint for controlling immune responses. Altered
regulation of this checkpoint can lead to aggravated autoimmu-
nity by overproduction of T helper cells that cause pathogenic
inﬂammation. Similarly, allograft rejection also depends on the
effectors that differentiate from allo-speciﬁc naïve T cells. In vitro
stimulation of naïve CD4 T cells in the presence of appro-
priate cytokines up-regulates master transcription factors that
instruct their differentiation into Th1, Th2, or Th17 inﬂamma-
tory T helper cells (Dong, 2010). When stimulated with IL-12
or interferon-γ (INF-γ), naïve T cells express the T-box tran-
scription factor T-bet as their lineage-speciﬁc transcription factor
and differentiate into Th1 cells that secrete IFN-γ as their sig-
nature cytokine. In the presence of IL-4, naïve T cells express
GATA3 as their lineage-speciﬁc transcription factor and differ-
entiate into Th2 cells that secrete the signature cytokines IL-4,
IL-5, and IL-13 (Murphy and Reiner, 2002). TCR stimula-
tion in the presence of IL-6 and TGF-β leads to up-regulation
of RORγt and differentiation of naïve T cells into Th17 cells
that produce IL-17, IL-21, IL-22, and GM-CSF. We compared
the differentiation of WT and PKC-θ−/− T cell under Th1,
Th2, and Th17 priming conditions in vitro to determine the
function of PKC-θ in these processes and found that PKC-
θ preferentially involved in the regulation of Th17 formation
(Kwon et al., 2012). We showed that puriﬁed naive PKC-θ−/−
T cells were defective in Th17 differentiation, whereas Th1 and
Th2 differentiation appeared normal. Activation of PKC-θ with
PMA promoted Th17 differentiation in WT but not PKC-θ−/−
T cells. Furthermore, PKC-θ−/− T cells had notably lower levels
of Stat3, a transcription factor required for Th17 differentiation,
and PMA markedly stimulated the expression of Stat3 in WT but
not PKC-θ−/− T cells. In contrast, activation of Stat4 and Stat6,
which are critical for Th1 and Th2 differentiation, was normal in
PKC-θ−/− T cells. Forced expression of Stat3 signiﬁcantly
increasedTh17differentiation inPKC-θ−/− Tcells, indicating that
reduced Stat3 levels were responsible for impaired Th17 differen-
tiation and that Stat3 lies downstream of PKC-θ. Constitutively
active PKC-θ orWT PKC-θ activated by either PMA or TCR cross-
linking, stimulated the expression of a luciferase reporter gene
driven by the Stat3 promoter. PKC-θ-mediated activation of the
Stat3 promoter was inhibited by dominant negative AP-1 and IκB
kinase-β, but stimulated by WT AP-1 and IκB kinase-β, suggest-
ing that PKC-θ stimulates Stat3 transcription via the AP-1 and
NF-κB pathways. Finally, conditions favoring Th17 differentia-
tion induced the highest activation level of PKC-θ. Altogether,
the data indicate that PKC-θ integrates the signals from the TCR
activatedwithTh17priming cytokines to up-regulate Stat3 viaNF-
κB and AP-1, which stimulate Th17 differentiation. The results
are also consistent with the observation that PKC-θ-deﬁcient
mice are resistant to the induction of experimental autoimmune
encephalomyelitis (EAE; Salek-Ardakani et al., 2005; Tan et al.,
2006), which is a Th17-associated autoimmune disease. In con-
trast, and although PKC-θ−/− mice have been reported to be
defective in development of Th1 and Th2 immune responses,
depending on the mouse model used (Marsland et al., 2004;
Salek-Ardakani et al., 2004; Healy et al., 2006), our in vitro assays
have shown that Th1 and Th2 differentiation is normal in the
absence of PKC-θ. In addition to the apparently different priming
conditions in vitro and in vivo, defects in other PKC-θ-regulated
functions such as survival are likely to contribute to the overall
defective Th1 and Th2 immune responses observed in PKC-θ−/−
mice in vivo. Although it is difﬁcult to deﬁne which PKC-θ-
regulated functions are responsible for the defective immune
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responses in vivo, we excluded the possibility that PKC-θ-regulated
survival affected our differentiation assays in vitro by adding
exogenous IL-2 which inhibits PKC-θ−/− T cell apoptosis (Man-
icassamy et al., 2006a). Altogether, both in vitro and in vivo
studies indicate that PKC-θ promotes the differentiation of Th17
cells that are associated with multiple autoimmune disorders
(Huang et al., 2007).
PKC-θ INHIBITS THE DIFFERENTIATION AND ENHANCES
SUPPRESSIVE FUNCTION OF Tregs
Naïve CD4+ T cells can differentiate into either inﬂammatory
effector T cells or Tregs (iTregs; Bettelli et al., 2006; Zhou et al.,
2008), two distinct subsets of T cell helpers with opposite func-
tions. A ﬁne balance between these two opposing T cell types is
required for a functional immune system. The activation of naïve
T cells in the presence of TGFβ induces expression of Forkhead
Box P3 (Foxp3), a master transcription factor instructing iTreg
differentiation, and is also a marker for iTreg (Curotto de Lafaille
and Lafaille, 2009). In contrast to iTregs, natural Tregs (nTregs)
are not induced but develop in the thymus. The fact that naïve
T cells can be differentiated into inhibitory iTregs suggests there
is a therapeutic value for such a conversion in the treatment of
autoimmunity. Our data has demonstrated that PKC-θ-mediated
signals inhibit iTreg differentiation (Ma et al., 2012).We found that
TGFβ-induced iTreg differentiation was enhanced in PKC-θ−/−
T cells or WT cells treated with a speciﬁc PKC-θ inhibitor, but
was inhibited by the PKC-θ activator PMA or by CD28 cross-
linking which enhances PKC-θ activation. Further, we showed that
PKC-θ−/− T cells had reduced activity of the AKT kinase, and
that the expression of a constitutively active form of AKT in
PKC-θ−/− T cells restored their ability to inhibit iTreg differen-
tiation. In addition, knockdown or over expression of the AKT
downstream targets FoxO1 and FoxO3a was found to inhibit
or promote iTreg differentiation in PKC-θ−/− T cells respec-
tively, indicating that the AKT-FoxO1/3A pathway is responsible
for the inhibition of iTreg differentiation downstream of PKC-θ.
Considering the positive role played by PKC-θ in the activation
and differentiation of naïve T cells into inﬂammatory T effector
cells (Altman et al., 2000; Sun et al., 2000; Pfeifhofer et al., 2003;
Marsland et al., 2004), together the data indicate that PKC-θ is
able to control T cell-mediated immune responses by shifting
the balance between the differentiation of effector T cells and
inhibitory Tregs.
In addition to Treg differentiation, a recent study also demon-
strated a role for PKC-θ in the regulation of the effector function
of Tregs (Zanin-Zhorov et al., 2010). Tregs inhibit inﬂammatory
effector T cell function via cell contact-dependent and inde-
pendent mechanisms (Sakaguchi et al., 2008). Such inhibitory
functions of Tregs are important for establishing tolerance mech-
anisms required to prevent activation of autoreactive T cells that
lead to autoimmunity (Sakaguchi et al., 2006; Shevach, 2006;
Shevach et al., 2006; Miyara and Sakaguchi, 2007). The deple-
tion of CD4+CD25+ Tregs from mice results in the develop-
ment of widespread autoimmune/inﬂammatory diseases such as
autoimmune gastritis, thyroiditis, type 1 diabetes, and inﬂam-
matory bowel disease. These autoimmune disorders are pre-
vented by reconstituting the mice with CD4+CD25+ Treg cells
(Sakaguchi et al., 1995; Singh et al., 2001), indicating a thera-
peutic potential for Tregs for the treatment of autoimmunity. To
increase the efﬁcacy of Treg-mediated inhibition, it is important
to enhance the suppressive function of Treg. Inhibition of PKC-θ
either by knockdown or a speciﬁc PKC-θ inhibitor has been shown
to signiﬁcantly boost the potential of Tregs to inhibit T cell acti-
vation (Zanin-Zhorov et al., 2010). However, in the presence of
TGFβ neutralizing antibody, the PKC-θ inhibitor fails to enhance
the suppressive function of Tregs, suggesting that inhibition of
PKC-θ stimulates Tregs to produce the TGFβ that is responsible
for inhibition of T cell activation. Interestingly, the suppressive
function of Treg was also enhanced by inhibiting the activation of
NF-κB, a critical downstream target of PKC-θ (Sun et al., 2000),
indicating the possibility that PKC-θ inhibitor enhances Treg func-
tion by blocking activation of the NF-κB pathway. Furthermore,
PKC-θ inhibitor-treated Tregs were more potent than untreated
Tregs in preventing inﬂammatory colitis in vivo (Zanin-Zhorov
et al., 2010), supporting the potential clinical application of PKC-
θ inhibitors for Treg-mediated treatment of autoimmunity. Taken
together, inhibition of PKC-θ can interfere with T cell-mediated
immunity by inhibiting inﬂammatory T cell differentiation, by
promoting Treg differentiation and by enhancing the suppressive
function of Tregs.
PKC-θ PLAYS A CRITICAL ROLE IN T CELL-DEPENDENT
AUTOIMMUNITY
Due to the unique roles played by PKC-θ in the regulation of
T cell activation and differentiation, PKC-θ is believed to be a
potential drug target and pharmaceutical companies have devel-
oped highly speciﬁc PKC-θ inhibitors (Cywin et al., 2007; Mosyak
et al., 2007). Mouse models of autoimmune diseases have been
used to deﬁne PKC-θ function in T cell-dependent autoimmu-
nity (Marsland and Kopf, 2008). Two independent studies have
shown that PKC-θ−/− mice were resistant to the induction of
Th2-dependent lung inﬂammation in airway hyper responsive-
ness (AHR; Marsland et al., 2004; Salek-Ardakani et al., 2004),
supporting a requirement for PKC-θ in Th2 type autoimmu-
nity. In contrast, PKC-θ played a lesser role in the development
of a similar lung inﬂammatory response mediated by Th1 cells
(Salek-Ardakani et al., 2004), suggesting different functions of
PKC-θ in Th1 and Th2 responses. However, PKC-θ was found
to be essential for both methylated BSA and type II collagen-
induced arthritis, a Th1-mediated autoimmunity disease (Healy
et al., 2006). The results suggest that PKC-θ function is dependent
on the model used. PKC-θ−/− mice were reported by two differ-
ent groups to be resistant to the development of Th17-mediated
EAE, themousemodel formultiple sclerosis (Salek-Ardakani et al.,
2005; Tan et al., 2006), indicating a requirement for PKC-θ in
Th17-dependent autoimmunity.
The evaluation of PKC-θ function in vivo is complicated by
several factors. First, PKC-θ function may be compensated for
in vivo. Most in vitro assays clearly indicated essential role of
PKC-θ in T cell functions (Manicassamy et al., 2006b). However,
we found that the requirement for PKC-θmaybe bypassed if T cells
are stimulated by overwhelmingly strong TCR signals such as high
concentrations of phorbol ester and ionomycin or anti-CD3/28
antibodies (unpublished data). It is therefore possible that PKC-θ
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function in vivo may also depend on the strength of TCR stimu-
lation. In contrast to in vitro assays using puriﬁed T cells, in vivo
immune responses involve many different types of cells that can
produce factors to compensate for PKC-θ function. For example,
one of themajor signaling pathways that PKC-θ regulates isNF-κB.
NF-κB can also be activated by PKC-θ-independent pathways such
as TNFα and IL-1 (Sun et al., 2000). Many in vivo inﬂammation
conditions produce TNFα and IL-1 inﬂammatory cytokines and
these cytokines are likely compensate for PKC-θ function at least
for the activation of NF-κB in T cells. Toll like receptors (TLR)
can also activate the NF-κB pathway and it was indeed found that
TLR-mediated signals can overcome the requirement for PKC-θ in
T cell activation and the development of autoimmune myocardi-
tis (Marsland et al., 2005). Second, autoimmune diseases usually
involve more than one type of T helper cell. For example, both
Th1 and Th17 responses are likely contribute to the development
of EAE (Salek-Ardakani et al., 2005). In humans, it is even more
difﬁcult to speciﬁcally deﬁne the types of T helper cells involved
in autoimmunity. Therefore, inhibition of PKC-θ may inhibit one
type of T helper, but not other types of T helpers that can induce
autoimmunity. Conversely, PKC-θ-mediated T cell differentiation
is not the only PKC-θ function essential for the development of
autoimmunity; PKC-θ also regulates other T cell functions includ-
ing activation and survival. Therefore, the observed defects in the
development of autoimmunity in PKC-θ−/− mice are likely to be
due to the disruption of several PKC-θ-regulated functions includ-
ing those that have not yet been identiﬁed. However, despite the
possible complications, the potential of PKC-θ as a drug target
has been indicated by a trial for the treatment of psoriasis (Skvara
et al., 2008). In this study, the clinical severity of psoriasis was
reduced up to 69%after 2weeks of treatmentwith a PKC inhibitor,
AEB071 which inhibits multiple isoforms of PKC with strong
speciﬁcity for PKC-θ, PKC-α, and PKC-β and lesser speciﬁcity
for PKC-δ, PKC-ε, and PKC-η. Other clinical trials are expected
because many companies have developed PKC-θ inhibitors. One
of potential trials will be systemic lupus erythematosus, because
patients with this disease show considerably enhanced activa-
tion of both PKC-θ and its potential upstream kinase GLK
(Chuang et al., 2011).
PKC-θ IS REQUIRED FOR NKT-MEDIATED
AUTOIMMUNE HEPATITIS
Autoimmune hepatitis (AIH) results from the mistaken attack
on healthy liver cells by an individual’s own immune system
(McFarlane, 1999). In mice, acute hepatitis can be induced by
treatment with concanavalin A (ConA), which causes rapid acti-
vation of CD1d-positive NK T cells. These activated NKT cells
produce large amounts of cytokines that cause strong inﬂam-
mation responsible for damaging liver tissues. Our research has
shown that PKC-θ−/− mice were resistant to ConA-induced hep-
atitis due to an essential requirement for PKC-θ during NKT
cell development and activation. A dose of ConA (25 mg/kg)
that was lethal to WT mice failed to cause death due to liver
injury in PKC-θ−/− mice (Fang et al., 2012). Correspondingly,
the ConA-induced production of cytokines such as IFNγ, IL-6,
and TNFα, which mediate the inﬂammation responsible for liver
injury, were signiﬁcantly lower in PKC-θ−/− mice. In addition,
upon stimulation with an NKT cell-speciﬁc lipid ligand, periph-
eral PKC-θ−/− NKT cells produced lower levels of inﬂammatory
cytokines than that of WT NKT cells, suggesting that activa-
tion of NKT cells requires PKC-θ. Our results suggest PKC-θ
is an essential molecule required for activation of NKT cells
to induce hepatitis (Fang et al., 2012), and thus, is a potential
drug target for prevention of autoimmune hepatitis. NKT cells
are also thought to be involved in liver injury induced by LPS,
α-galactosylceramide (α-GalCer), Salmonella infection, chronic
hepatitis C infection, and primary biliary cirrhosis (Ishigami et al.,
1999; Kawano et al., 1999; Kaneko et al., 2000; Kato et al., 2000;
Kim et al., 2002). Inhibition of PKC-θ is also likely to have thera-
peutic value in the treatment of liver injury in patients with these
conditions.
PKC-θ PLAYS A CRITICAL ROLE IN ALLOIMMUNE
RESPONSES ESSENTIAL FOR TRANSPLANT REJECTION
Solid organ transplants that beneﬁt end-stage organ failure
patients are severely limited by the occurrence of rejection. Allore-
active T cells are critical targets for tolerance induction since
they mediate the immune responses required for rejection. The
alloreactive T cell pool is very large (Suchin et al., 2001), which
explains why immune responses against allografts are at least two
orders of magnitude stronger than immune responses against a
speciﬁc antigen. Therefore, long-term tolerance to allografts is
extremely difﬁcult to establish. The initial evidence for require-
ment of PKC-θ in alloresponses came from the impaired in vitro
mixed lymphocyte reaction of PKC-θ−/− T cells (Sun et al., 2000).
Injection of allogeneic cells into the footpad of PKC-θ-deﬁcient
mice provoked a signiﬁcantly diminished local T cell response
compared toWTmice similarly challenged, suggesting an essential
role for PKC-θ in the allo-reaction in vivo (Anderson et al., 2006).
We tested PKC-θ function in transplant rejection using a cardiac
allograft model (Manicassamy et al., 2008). Rag1−/− mice recon-
stituted with WT T cells readily rejected fully mismatched cardiac
allografts, whereas, Rag1−/− mice reconstituted with PKC-θ−/−
T cells failed to promote rejection, suggesting that PKC-θ is
required for T cell-mediated allograft rejection. One of the
important mechanisms responsible for establishing tolerance to
allografts is to reduce thenumber of alloreactiveT cells by inducing
apoptosis (Wells et al., 1999). Since PKC-θ is required for survival
of activated T cells (Manicassamy et al., 2006a), we therefore tested
the role of PKC-θ-regulated survival in cardiac allograft rejec-
tion and demonstrated that the transgenic expression of Bcl-xL in
PKC-θ−/− T cells was sufﬁcient to restore cardiac allograft rejec-
tion (Manicassamy et al., 2008). This result suggests that apoptosis
of alloreactive T cells in the absence of PKC-θ is responsible for
the observed tolerance to cardiac allografts. Alloreactive T cells can
be tolerized through anergy, suppression and deletion. Tolerizing
mechanisms through anergy and Treg-mediated suppression are
unlikely change the size of alloreactive T cell pool which is ready
to destroy allografts. This is the problem for cyclosporin A (CsA),
the most successful immunosuppressive drug used clinically so
far. CsA prevents apoptosis of alloreactive T cells by inhibition
of T cell activation (Li et al., 1999), resulting in accumulation of
large amounts of alloreactive T cells that destroy allografts once
the immunosuppressive drugs are discontinued (Li et al., 2001).
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Therefore, prevention of allograft rejection usually requires trans-
plant recipients to take life-long immunosuppressive drugs, which
can result in complications including infections and malignancy.
Whereas, deletion induces tolerance by decreasing the number
of alloreactive T cells via apoptosis, and thus avoids the poten-
tial risk of accumulating alloreactive T cells. In addition to an
adoptive transfer model, we also tested cardiac rejection using
intact PKC-θ−/− mice. PKC-θ−/− mice displayed delayed, but
successful cardiac allograft rejection, suggesting there was some
compensation for the missing PKC-θ function. Finally, a sub-
therapeutic dose of anti-CD154 antibody or CTLA4-Ig, which was
not sufﬁcient to prevent cardiac allograft rejection in WT mice,
prevented heart rejection in PKC-θ−/− mice. PKC-θ−/− mice
treated with sub-therapeutic doses of Anti-CD154 or CTLA4-Ig
also accepted donor-type second cardiac allografts but rejected
third-party allografts (Wang et al., 2009). Thus, in combination
with other treatments, the inhibition of PKC-θ allows long-
term survival of cardiac allografts (Manicassamy et al., 2008;
Wang et al., 2009).
In addition to heart rejection, the role of PKC-θwas also exam-
ined in a bone marrow transplantation (BMT) model (Valenzuela
et al., 2009). BMT is used to replace damaged bone marrow with
healthy stem cells or used as therapy for hematopoietic malig-
nancies. In the latter case, allogeneic BMT boosts the patient’s
immune system to aid in ﬁghting against the cancer, which is
called the graft-versus-leukemia (GVL) effect. However, graft-
versus-host disease (GVHD), a potentially lethal consequence of
BMT, limits the clinical application of this very effective treat-
ment. Alloreactive donor T cells recognize the mismatched MHC
of the recipient and undergo robust activation, expansion, and dif-
ferentiation, resulting in GVHD, which causes severe damages to
multiple tissues including gut, liver, skin, and kidney (Shlomchik,
2007). Immunosuppressive drugs are therefore needed clinically
to prevent GVHD-induced damage. However, commonly used
immunosuppressive drugs such as CsA and FK506 also inhibit
the immune response against pathogens as well as tumors (GVL),
and consequently limit the effects of GVL on the elimination of
residual tumor cells (Reddy et al., 2005). The optimal immuno-
suppressive regimens are able to prevent GVHD, but also preserve
the immune responses against infectious pathogens. Similar to
WT mice, PKC-θ−/− mice have the ability to respond to infec-
tion by the listeria bacteria and MCMV virus (Valenzuela et al.,
2009). Moreover, PKC-θ−/− mice survived the BMT procedure
and did not develop GVHD, whereas majority of WT mice died
from GVHD. More importantly, PKC-θ−/− mice retained their
ability to induce rejection of tumors. This study demonstrated that
PKC-θ inhibitor-based immunosuppressive regimens are able to
prevent GVHD but also preserve the protective immune response
against infections and tumors.
CONCLUSION
PKC-θ controls fundamental functions of T cells including acti-
vation, differentiation, and survival via NF-κB, AP-1, and NFAT
pathways. PKC-θ also regulates T cell-mediated immune responses
in vivo and selective PKC-θ inhibitors are believed to have the
potential for clinical application in the treatment of autoimmunity
and prevention of allograft rejection. However, PKC-θ function in
T cell-mediated immune responses is dependent on the mouse
models used. Therefore, the mechanisms involved in each of the
diseases should be carefully examined. More questions need to
be addressed prior to the clinical application of PKC-θ inhibitors
including how the inhibition of PKC-θ affects the function of other
tissues in vivo. It is encouraging to report that many pharmaceu-
tical companies have developed selective PKC-θ inhibitors, and
therefore many PKC-θ-regulated functions can be evaluated using
these inhibitors instead of PKCθ−/− mice, which have potential
developmental caveat. With the availability of PKC-θ inhibitors, it
is now possible to test their efﬁcacy in mouse models of human
autoimmune diseases including EAE and arthritis, which are likely
to lead to clinical trials of PKC-θ-based treatments for human
diseases.
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